Blah ...blah...blah....we lost some money......blah blah blah.....“This is an exciting time as we focus on the planned submission of our NDA for pimavanserin in Parkinson’s disease psychosis near the end of this year and continue building the commercial infrastructure necessary to support the planned launch of pimavanserin. Given the demonstrated antipsychotic effects, benefits on sleep, and favorable safety profile we’ve observed in the clinic to date, we are also very excited about the opportunity to advance pimavanserin in other indications. To that end, we continue to advance enrollment of our ongoing Phase II study of pimavanserin in Alzheimer’s disease psychosis and prepare for additional studies to evaluate the clinical utility of pimavanserin in other areas of significant unmet medical need.” Blah ...blah...blah....we are all gonna be Millionairs....Blah blah blah....
Well Allergan could bid all they please but they would NEVER win. Too many heavy hitters to compete with. eg, MRK...PFE...etc.
Safe Harbor or not, it could POP the stock and wash a ton of shorts right off the plate. Holding a short position into this Qrpt is very risky. I hope the shorts HOLD their position all the way to $40.
longs that will win this battle. Unlike INO or MNKD...this stock will not need a partner. ACAD has a ton of cash and a one of a kind, first in its class BILLION DOLLAR DRUG.
You might also check out MRK, they got some cash to beat PFE to the punch...they could also buy ACAD ...their q rtp will be next week ( ? news?) and their New Drug application is just around the corner.
Not so much another inhaled insulin , Affrezza. There is risk of marketing failure like PFE's inhaled insulin that FAILED BADLY. Lower than expected sales, disappointed shareholders who bought in too high are mounting up daily= Too many bag holders will sell off all the up coming rallies ( if there are any). Does Afrezza have value ...yes. How much...not as much as the Rah Rah crowd thinks. Black Box Warning can be a killer for many new drugs, Stiff competition from those excellent products like Flex Pen's, that has a strong brand loyalty. Patients love their Pen's, require no refrigeration and you hardly feel the needle. Drug insurance protocols which protect the bottom line that will keep the sales less than expected. Generics are always recommended as a first line treatment by ALL drug insurers. Probably only 1-3% of the diabetic population will ever use this drug. Not even close to 10%. The value in MNKD is the technology. If they get other products to market that would really increase the MK. THEY MUST HAVE A PARTNER or this stock will never get off this Short Controlled trading pattern.
Think of the IBB like ACAD...but with a lower Beta or vice versa think of ACAD like the IBB but with a HIGHER Beta.
Type Value Conf.
resist. 30.10 2
resist. 28.78 2
resist. 25.34 3
resist. 24.88 2
resist. 23.75 5
resist. 22.44 3
resist. 22.08 2
resist. 21.54 3
resist. 20.93 9
supp 20.04 6
supp 19.27 4
supp 17.91 5
the Fabulous town of "New Drug Application" and that Hot Hot town of "40 Dollar share". All aboard !!!
They need CASH FAST. They need about 150-200 Million to get production rolling for 1+years. The amount of cash they have now would start up production and perhaps take it about 3-6 months. So either the CEO has to get a partner or....(Ugh) SELL SOME SHARES. So to get about $160 Million at this point he would have to Sell about 20,000,000 Shares at about $8 ( ? lower to make it attractive to Big Investors).